Dynavax Says Investigational Shingles Vaccine At Par With GSK's Vaccine In Early-Stage Study Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.
Wall Street's Top 10 Stock Calls This Week - Saturday, Feb. 15 What has Wall Street been buzzing about this week? Here is a look at the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Feb. 10-14, 2025.
Goldman Sachs Turns Bearish On Vaccine Maker Dynavax Amid Shingles And Hepatitis B Uncertainty Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.
DVAX Stock Earnings: Dynavax Technologies Beats EPS, Misses Revenue for Q2 2024 DVAX stock results show that Dynavax Technologies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
FDA Declines To Approve Expanded Use of Dynavax's Hepatitis B Vaccine In Hemodialysis Patients Latest regulatory update from Dynavax on HEPLISAV-B vaccine regimen for adults on hemodialysis, with FDA's Complete Response Letter.
DVAX Stock Earnings: Dynavax Technologies Misses EPS, Misses Revenue for Q1 2024 DVAX stock results show that Dynavax Technologies missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
